Skip to Main Content

And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda appears modest for now. We plan to promenade with the official mascot, catch up on our reading, and take a nap or three. And what about you? This is a fine time to keep warm in front of the telly or face time with friends. Or you could brave the temperatures and enjoy the great outdoors, perhaps frolic in the snow, if any landed your way. Well, whatever you do, have a grand time. But be safe, wear a mask. Enjoy, and see you soon. …

More than 65 institutional investors are urging the directors of companies making Covid-19 vaccines to tie executive compensation to vaccine equity in hopes of holding management “accountable” for contributing to a global health problem, STAT writes. In a series of letters, the investors asked the heads of the board compensation committees at Pfizer (PFE), Johnson & Johnson (JNJ), Moderna (MRNA), and AstraZeneca (AZN) to adopt goals outlined recently by the World Health Organization to ensure 70% of the global population is vaccinated by the end of 2022.


In the latest bid to expand access to the Pfizer Covid-19 pill, a nonprofit group and an association of pharmacists are seeking to make it possible for generic manufacturers to sell the medicine in Chile, which was excluded from a recent licensing deal the drug maker reached for its pill to become available in mostly poor countries, STAT reports. The plan hinges on convincing the Chilean government to issue a compulsory license and comes after Pfizer reached a licensing agreement with the Medicines Patent Pool to strike deals with other manufacturers to provide generic versions of the pill to 95 low- and middle-income countries. Chile, however, is not on the list.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment

There was an error saving your display name. Please check and try again.